Results 31 to 40 of about 6,610 (157)

THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS

Вестник анестезиологии и реаниматологии, 2019
Goal: to evaluate the efficacy and safety of domestic (home-produced) recombinant factor VIIa (Coagil VII) for massive bleeding and haemostasis disordes treatment in thoracic aorta surgery. Methods.
N. A. TREKOVA, D. A. GUSKOV, A. V. GONCHAROVA, B. A. AKSELROD   +3 more
doaj   +1 more source

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3

Haemophilia, EarlyView.
ABSTRACT Introduction Tissue factor pathway inhibitor (TFPI), a key regulator of tissue factor‐initiated coagulation through FXa‐dependent inhibition of the tissue factor‐FVIIa complex, has emerged as a promising target for restoring thrombin generation.
Mankai Ju, Feng Xue, Wei Sun, Fang Li, Ting Xu, Renchi Yang   +5 more
wiley   +1 more source

Diffuse Alveolar Hemorrhage following Allogeneic Stem Cell Transplantation treated successfully with Recombinant Factor VIIa

Mediterranean Journal of Hematology and Infectious Diseases, 2014
Diffuse alveolar hemorrhage is a serious complication post stem cell transplantation with no proven definitive treatment, resulting in high mortality. Recombinant factor VIIa has been occassionaly used in such patients with good results. We report here a
Dharma Choudhary, Sanjeev Kumar Sharma, Nitin Gupta, Anil Handoo   +3 more
doaj  

Recombinant Factor VIIa in the Treatment of Bleeding [PDF]

American Journal of Clinical Pathology, 2004
Recombinant factor VIIa (rFVIIa) has become available for treating people with hemophilia with inhibitors who experience bleeding or require surgery. It has become apparent that rFVIIa is useful in controlling bleeding in a variety of clinical situations. This review attempts to collate and summarize the nonhemophilia applications of rFVIIa.
Madhu V, Midathada, Paulette, Mehta, Milton, Waner, Louis M, Fink   +3 more
openaire   +2 more sources

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Platelet Levels Associated With Bleeding Risk for Dental Interventions: A Systematic Review

Oral Diseases, EarlyView.
ABSTRACT Objectives To evaluate evidence in relation to postoperative bleeding in humans aged ≥ 16 with preoperative platelet counts < 50,000/μL, compared to those above, undergoing dental interventions. Methods Quantitative synthesis without meta‐analysis was conducted through an electronic search conducted on Ovid MEDLINE and Embase from 1946 to ...
Guang Xu David Lim, Fatima Al Sarraf, Hana Cho, Navdeep Kumar   +3 more
wiley   +1 more source

Recombinant-activated factor VII in patients with uncontrolled bleeding: A retrospective observational analysis

Asian Journal of Transfusion Science, 2012
Background: Factor VIIa (recombinant) has an off-label use to control life-threatening bleeding that is refractory to other measures and was shown to decrease transfusion requirements.
Said D Abuhasna, Amer H Al Jundi, Hashem A Tarifi   +2 more
doaj   +1 more source

Oral wound healing in the elderly: Mechanisms, challenges, and innovations

Periodontology 2000, EarlyView.
Abstract Objective This narrative synthesizes current knowledge on the biological mechanisms, clinical challenges, and regenerative innovations for optimizing intraoral wound healing in the elderly. Methods Narrative review of preclinical and clinical studies addressing age‐related changes in the four canonical wound‐healing phases (hemostasis ...
Ann M. Decker, Sandra H. Stuhr, Gustavo Avila‐Ortiz, Andrea Pilloni, Lorenzo Marini, Rogerio Castilho, Beth I. Wallace, Yvonne L. Hernandez‐Kapila   +7 more
wiley   +1 more source

Normal thromboelastography with a markedly prolonged activated partial thromboplastin time in severe prekallikrein deficiency: Implications for perioperative hemostatic assessment

Transfusion, EarlyView.
Abstract Background Prekallikrein (PK) deficiency is a rare contact factor deficiency that can markedly prolong the activated partial thromboplastin time (aPTT) without a bleeding phenotype. Because viscoelastic hemostatic assays also rely on contact activation, their behavior in severe PK deficiency is relevant to perioperative evaluation of isolated ...
Jeremy W. Jacobs, Anton Matafonov, Patricia G. Baxter, Qiufang Cheng, Garrett S. Booth, Deva Sharma, Benjamin F. Tillman, David Gailani   +7 more
wiley   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, Volume 20, Issue 7, Page 1780-1799, July 2026.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source